Aisling Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Aisling Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,123,630	Closed	-$148M	–	17
2020 Q4	$148M	Hold	1,123,630	–	–	25.39%	2
2020 Q3	$56.8M	Hold	1,123,630	–	–	18.14%	2
2020 Q2	$53.6M	Hold	1,123,630	–	–	20.44%	2
2020 Q1	$55M	Hold	1,123,630	–	–	23.98%	2
2019 Q4	$64.5M	Hold	1,123,630	–	–	24.71%	2
2019 Q3	$40.4M	Hold	1,123,630	–	–	21.07%	2
2019 Q2	$34.9M	Hold	1,123,630	–	–	14.92%	2
2019 Q1	$26.3M	Hold	1,123,630	–	–	20.07%	1
2018 Q4	$15.5M	Buy	+1,123,630	New	+$14.2M	16.29%	2

Aisling Capital Management's EIDX Position: Q1 2021 in Review

Aisling Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 1,123,630 shares — an estimated $148M sold.

Aisling Capital Management first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $148M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Aisling Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Aisling Capital Management sold 1,123,630 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $148M.
Aisling Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Aisling Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $148M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Aisling Capital Management's 13F filing for Q1 2021, filed 14 May 2021.